- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02055729
Changes in Bacterial Flora Among Patients With Pelvic Bedsores: a Prospective Pilot Study (EscaFlor)
Changes in Cutaneous, Digestive and Urinary Bacterial Flora Among Patients With Pelvic Bedsores: a Prospective Pilot Study
Study Overview
Status
Conditions
Detailed Description
The secondary objectives of this study are:
A. To compare bacterial communities collected from superficial versus deep samples of stage 3 or 4 sacral bedsores using metagenomics and standard culturing methods.
B. To characterize the evolution of digestive bacterial flora in the same patients over a period of 28 days. Changes in terms of pathogenic, potentially pathogenic and non-pathogenic will be described, as well as the appearance of resistance phenotypes.
C. To characterize the evolution of urinary bacterial flora in the same patients over a period of 28 days. Changes in terms of pathogenic, potentially pathogenic and non-pathogenic will be described, as well as the appearance of resistance phenotypes.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
-
Montpellier, France, 34090
- Centre Mutualiste Neurologique Propara
-
Nîmes, France, 30000
- Laboratoire d'Etude et de Recherche en Environnement et Santé, Unité Biodiagnostic, UNIMES
-
Nîmes Cedex 2, France, 30908
- Unité U1047 "Bacterial virulence and infectious diseases", UFR de Médecine
-
Nîmes Cedex 9, France, 30029
- CHRU de Nîmes - Hôpital Universitaire Carémeau
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- The patient was correctly informed about study implementation, its objectives, constraints and patient rights
- The patient must have given his/her informed and signed consent
- The patient must be insured or beneficiary of a health insurance plan
- The patient is available for 28 days of follow-up
- The patient has one or more pelvic pressure ulcers (bedsores)(stage 3 or 4 only). Note: Patients with bedsores of varying stage will be included for the wound corresponding to the highest stage. If the patient has multiple bedsores of the same stage, the deepest wound will be selected.
- The patient requires a modern wound dressings (i.e. not tulle or gauze) without added bactericidal or antibiotic elements
- The patient is hospitalized ant the Propara neurological rehabilitation center (Montpellier, France)
- The patient has not received antibiotics in the last 14 days.
Exclusion Criteria:
- The patient is participating in another study, or has participated in another study in the last 3 months
- The patient is in an exclusion period determined by a previous study
- The patient is under judicial protection, under tutorship or curatorship
- The patient refuses to sign the consent
- It is impossible to correctly inform the patient
- The patient is pregnant, parturient, or breastfeeding
- The patient is already included in the present study
- The patient has sacral pressure ulcers of only stages 1 or 2, or does not have a sacral pressure ulcer
- Patient under curative anticoagulation
- Patient who received antibiotics within 14 days before inclusion (however, after inclusion, the patient can be treated with antibiotics if necessary)
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
|---|---|
|
The study population
The proposed study is a prospective, single-center pilot study lasting 28 days. Our goal is to study the temporal evolution of the bacterial communities present in the skin and digestive flora (stool) of spinal cord injured persons having one or more sacral bedsores. The study timespan can include treatment initiation, notably of antibiotics. Urinalysis for studying urinary flora will simultaneously occur. For a description of the study population, see the inclusion/exclusion criteria. Intervention: Superficial bedsore sample Intervention: 3mm tissue punch biopsy Intervention: Stool sample Intervention: Urine sample |
Bacterial samples will be collected using deep level tissue biopsy using a Steifel punch of 3 mm in diameter (days 0 and 28).
Bacterial samples will be taken from the surface of the bedsore via swabbing.
(days 0 & 28)
Stool samples will be collected on days 0 and 28.
Urine samples will be collected on days 0 and 28.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
List of pathogenic, potentially pathogenic and commensal bacterial species in superficial and deep bedsore samples
Time Frame: Baseline (day 0)
|
At the individual level
|
Baseline (day 0)
|
|
List of pathogenic, potentially pathogenic and commensal bacterial species in superficial and deep bedsore samples
Time Frame: Day 28
|
At the individual level
|
Day 28
|
|
Percentage of pathogenic, potentially pathogenic, and commensal bacterial species in superficial and deep bedsore samples
Time Frame: baseline (day 0)
|
Calculated over the entire study population
|
baseline (day 0)
|
|
Percentage of pathogenic, potentially pathogenic, and commensal bacterial species in superficial and deep bedsore samples
Time Frame: Day 28
|
Calculated over the entire study population
|
Day 28
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Classification of bacteria present according to respiratory type, gram negative/positive, shape, and resistance phenotypes.
Time Frame: baseline (Day 0)
|
Based on superficial and deep bedsore samples.
|
baseline (Day 0)
|
|
Classification of bacteria present according to respiratory type, gram negative/positive, shape, and resistance phenotypes.
Time Frame: Day 28
|
Based on superficial and deep bedsore samples.
|
Day 28
|
|
List of pathogenic, potentially pathogenic and commensal bacterial species in stool samples
Time Frame: baseline (day 0)
|
baseline (day 0)
|
|
|
List of pathogenic, potentially pathogenic and commensal bacterial species in stool samples
Time Frame: Day 28
|
Day 28
|
|
|
List of pathogenic, potentially pathogenic and commensal bacterial species in urine samples
Time Frame: baseline (day 0)
|
baseline (day 0)
|
|
|
List of pathogenic, potentially pathogenic and commensal bacterial species in urine samples
Time Frame: day 28
|
day 28
|
Collaborators and Investigators
Investigators
- Study Director: Catherine Dunyach-Remy, PhD, Centre Hospitalier Universitaire de Nīmes
Publications and helpful links
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- LOCAL/2013/CDR-01
- 2014-A00534-43 (OTHER: RCB number)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Bedsore
-
King Abdullah Medical CityRecruitingPressure Injury | Pressure Ulcer, Buttock | Pressure Injury Stage 2 | Pressure Ulcers Stage II | BedsoreSaudi Arabia
-
University Hospital, MontpellierHill-RomTerminatedSpinal Cord Injury | Pressure Ulcer | Paraplegia | BedsoreFrance
-
University Hospital, MontpellierInstitut National de la Santé Et de la Recherche Médicale, France; Hill-RomTerminatedSpinal Cord Injury | Pressure Ulcer | Paraplegia | BedsoreFrance
Clinical Trials on 3mm tissue punch biopsy
-
Chandan SenTerminatedWound Leg | Non-Diabetic Patients | Chronic Ulcer Leg/FootUnited States
-
Maastricht University Medical CenterCompletedBasal Cell CarcinomaNetherlands
-
Maastricht University Medical CenterRecruitingBasal Cell Carcinoma | Optical Coherence TomographyNetherlands
-
University of FloridaDentsply Implants Manufacturing GmbHWithdrawnGingival Recession, Generalized | Graft Reaction
-
M.D. Anderson Cancer CenterUnited States Department of DefenseCompletedMelanoma | Sarcoma | Breast Cancer | Malignant Female Reproductive System Neoplasm | Genitourinary CancerUnited States
-
Catholic University of the Sacred HeartCompletedOral Lichen Planus | BiopsyItaly
-
Duke UniversityTerminated
-
Tampere University HospitalOlfactomics OyRecruitingOral Squamous Cell CarcinomaFinland
-
Tampere University HospitalOlfactomics OyRecruiting
-
Ohio State UniversityCompletedCellulitis | PseudocellulitisUnited States